Empagliflozin
- Generic Name
- Empagliflozin
- Brand Names
- Glyxambi, Jardiance, Synjardy, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27ClO7
- CAS Number
- 864070-44-0
- Unique Ingredient Identifier
- HDC1R2M35U
- Background
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies, for the management of type 2 diabetes mellitus.
...
- Indication
Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes, either alone or in combination with metformin or linagliptin. It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease, either alone or a...
- Associated Conditions
- Cardiovascular Mortality, Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Hospitalizations, Symptomatic Congestive Heart Failure, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- Monotherapy
Replication of the EMPAREG Diabetes Trial in Healthcare Claims
- First Posted Date
- 2020-01-02
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 103752
- Registration Number
- NCT04215536
- Locations
- 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 530
- Registration Number
- NCT04157751
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Grady Memorial Hospital, Atlanta, Georgia, United States
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency
- Conditions
- Interventions
- First Posted Date
- 2019-10-24
- Last Posted Date
- 2019-10-28
- Target Recruit Count
- 5
- Registration Number
- NCT04138251
- Locations
- 🇧🇪
Cliniques universitaires Saint-Luc, Brussels, Belgium
A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2021-03-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 9571
- Registration Number
- NCT04098575
- Locations
- 🇩🇪
Diabetes Agenda 2010 GmbH, Mahlow, Germany
Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2019-07-10
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04014192
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26774
- Registration Number
- NCT03993132
- Locations
- 🇩🇰
Department of Clinical Epidemiology - Aarhus Unversiteteshospital, Aarhus, Denmark
Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting
- Conditions
- Interventions
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2022-06-07
- Target Recruit Count
- 28
- Registration Number
- NCT03979352
- Locations
- 🇨🇦
Sinai Health System, Toronto, Ontario, Canada
🇨🇦McGill University, Montréal, Quebec, Canada
DIA_CENTRAL:T2D Treatment Pattern in Central Europe
- First Posted Date
- 2019-01-17
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 4083
- Registration Number
- NCT03807440
- Locations
- 🇷🇺
Penza regional clinical hospital named after N.N. Burdenko, Center Nr.: 70095, Penza, Russian Federation
🇧🇬MC "Diamedical 2013" OOD, Center Nr.: 35902, Dimitrovgrad, Bulgaria
🇧🇬"Medical Center-Razgrad"OOD, Center Nr.: 35910, Razgrad, Bulgaria
Drug Interaction Study Between Dorzagliatin and Empagliflozin
- First Posted Date
- 2019-01-02
- Last Posted Date
- 2020-03-25
- Lead Sponsor
- Hua Medicine Limited
- Target Recruit Count
- 16
- Registration Number
- NCT03790787
- Locations
- 🇺🇸
Frontage Clinical Services Inc., Hackensack, New Jersey, United States
Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration
- Conditions
- Interventions
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1502
- Registration Number
- NCT03764631
- Locations
- 🇸🇦
Dr. Soliman Fakeeh Hospital, Jeddah, Saudi Arabia
🇸🇦Shifa Hospital, Makkah, Saudi Arabia
🇸🇦Prince Fahad bin Sultan hospital, Tabuk, Saudi Arabia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.